DAX25.040 +0,2%Est506.283 -0,7%MSCI World4.343 -0,1%Top 10 Crypto7,7900 +3,5%Nas26.040 -0,7%Bitcoin53.415 +4,1%Euro1,1379 ±-0,0%Öl71,19 -2,4%Gold4.039 +0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SpaceX A42D4F Deutsche Telekom 555750 Volkswagen (VW) vz. 766403 NVIDIA 918422 Infineon 623100 Bayer BAY001 SAP 716460 Siemens Energy ENER6Y Lufthansa 823212 Micron Technology 869020 Microsoft 870747 Allianz 840400 BMW 519000 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet Handel stabil -- US-Börsen schwächer -- Chipaktien mit Rekordquartal -- Lime-IPO geglückt -- Meta, Alcoa, ServiceNow, Bloom Energy, Novo Nordisk, Bayer, Samsung, SK hynix im Fokus
Top News
Zwei Krypto-Schwergewichte, ein Kursziel: Bitcoin-Boden bei 40.000 bis 44.000 US-Dollar? Zwei Krypto-Schwergewichte, ein Kursziel: Bitcoin-Boden bei 40.000 bis 44.000 US-Dollar?
OpenAI und Broadcom präsentieren Jalapeño: Erster eigener KI-Chip soll NVIDIA-Abhängigkeit verringern OpenAI und Broadcom präsentieren Jalapeño: Erster eigener KI-Chip soll NVIDIA-Abhängigkeit verringern
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

BeiGene Aktie

Kaufen
Verkaufen
BeiGene Aktien-Sparplan
256,00 EUR +6,00 EUR +2,40 %
BMN
290,79 USD +5,81 USD +2,04 %
BTT
finanzen.net zero
BeiGene jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.26,02 Mrd. EUR

KGV119,81Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1437N

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS07725L1026

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolONC

BeiGene Aktien News

DatumMeistgelesen
PR NewswireOncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
PR NewswireOncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
PR NewswireOncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
Wer­bungBeiGene-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireOncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
PR NewswireOncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
PR NewswireOncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
PR NewswireOncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
PR NewswireOncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
PR NewswireOncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
PR NewswireOncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
PR NewswireKey Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
PR NewswireKey Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
PR NewswireOncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
PR NewswireOncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
PR NewswireOncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
PR NewswireOncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
PR NewswireOncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
PR NewswireOncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
PR NewswireOncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
PR NewswireOncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
PR NewswireOncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
PR NewswireOncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
PR NewswireOncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
PR NewswireOncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
PR NewswireOncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
PR NewswireOncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
PR NewswireOncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
PR NewswireOncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
PR NewswireOncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
PR NewswireOncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
PR NewswireOncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
PR NewswireOncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
PR NewswireOncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
PR NewswireOncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
PR NewswireOncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
PR NewswireOncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
PR NewswireOncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
PR NewswireOncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
PR NewswireOncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
PR NewswireOncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

BeiGene News

BeiGene News: auf dieser Seite finden Sie alle BeiGene News und Nachrichten zur BeiGene Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch BeiGene News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um BeiGene News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.